Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Medication Persistence for Psoriatic Arthritis in a Brazilian Real-World Setting

2019; Future Science Ltd; Volume: 5; Issue: 2 Linguagem: Inglês

10.4155/fsoa-2018-0101

ISSN

2056-5623

Autores

Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro dos Santos, Alessandra Maciel Almeida, Alexander Itria, Adriana María Kakehasi, Juliana Álvares-Teodoro, Francisco de Assis Acúrcio,

Tópico(s)

Rheumatoid Arthritis Research and Therapies

Resumo

To evaluate the persistence of biological (TNF inhibitor [anti-TNF]) and synthetic (conventional synthetic disease-modifying antirheumatic drugs [csDMARDs]) antirheumatic agents for psoriatic arthritis and their associated factors.A historical cohort was developed. Persistence and associated factors were evaluated at 6 and 12 months.A total of 161 patients were included. The anti-TNF treatment presented higher persistence as compared with csDMARDs at 6 (83.4 vs 50.8%; p < 0.05) and 12 months (66.4 vs 35.6%; p < 0.05). From anti-TNFs, adalimumab and etanercept presented similar persistence, along with leflunomide and methotrexate among the csDMARDs. The factors associated with non-persistence with regard to anti-TNF agents were female sex and use of infliximab.Anti-TNF agents are important therapeutic alternatives and present lower rates of discontinuation as compared with csDMARDs.

Referência(s)